Alpa Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Alpa Laboratories Ltd reported a 4.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 26.3%.
• Its expenses for the quarter were down by 0.2% QoQ and 30.1% YoY.
• The net profit decreased 73.7% QoQ and decreased 123.6% YoY.
• The earnings per share (EPS) of Alpa Laboratories Ltd stood at 0.24 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alpa Laboratories Ltd is a company operating within the pharmaceutical industry. It is primarily engaged in the manufacturing and distribution of pharmaceutical products. These products typically include a wide range of formulations such as tablets, capsules, and other medicinal preparations. The company serves both domestic and international markets, adhering to industry standards and regulations. Recent major developments regarding Alpa Laboratories Ltd are not provided in the available data, hence any updates or strategic changes in the company’s operations remain unspecified.

Revenue

In the fourth quarter of FY26, Alpa Laboratories Ltd reported a total income of ₹31.24 crores. This represents an increase of 4.3% from the previous quarter (Q3FY26), where the total income was ₹29.96 crores. However, when comparing year-over-year, the total income decreased by 26.3% from Q4FY25, where it was ₹42.40 crores. The quarterly increase suggests a modest improvement in revenue generation, while the annual decline highlights a significant decrease in income over the year.

Profitability

For Q4FY26, Alpa Laboratories Ltd recorded a profit before tax of ₹2.19 crores, showing a 25.1% increase from the previous quarter's figure of ₹1.75 crores. When compared to Q4FY25, the profit before tax increased by 5.3%, up from ₹2.08 crores. Tax expenses for Q4FY26 were ₹1.69 crores, a significant change from a tax credit of ₹-0.16 crores in Q3FY26 and a decrease from ₹4.20 crores in Q4FY25. The profit after tax for Q4FY26 was ₹0.50 crores, a decrease of 73.7% from ₹1.90 crores in Q3FY26 but an improvement from a loss of ₹-2.12 crores in Q4FY25. Earnings per share for Q4FY26 stood at ₹0.24, compared to ₹0.90 in Q3FY26 and a negative ₹-0.95 in Q4FY25.

Operating Metrics

The total expenses for Alpa Laboratories Ltd in Q4FY26 were ₹28.17 crores, slightly down by 0.2% from Q3FY26's ₹28.22 crores. Compared to Q4FY25, there was a notable reduction of 30.1% from ₹40.32 crores. This reduction in expenses year-over-year suggests a decrease in operational costs or a change in cost management practices over the period. While the quarter-over-quarter change is minimal, the annual decrease in expenses aligns with the reduction in total income over the same period. Such changes in operating expenses play a crucial role in the company's financial health and profitability, impacting the bottom line significantly.